ClinicalTrials.gg
RecruitingNCT07080567MASTERUpdated Aug 12, 2025

Manipulating the Peri-Infarct Area Using Maraviroc to Enhance Motor Skills After Stroke

A Phase 2 interventional study of Maraviroc and Mannitol in Ischemic Stroke, Stroke and Stroke Acute, sponsored by Emmanuel Carrera. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-12.

Sponsored by Emmanuel Carrera · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 86 studies in Ischemic Stroke with a site in Switzerland — 27 open to participants now, 33 under way, 3 of them phase 3. Ischemic Stroke · Switzerland.

Planned enrollment
34th of 42
80 · median 487
Started
2025
with 9 others
Phase 2
4 of 86
1 open now
Primary completion
2027-12
later than 23 of 32 live
Registered
82nd of 86
by date

Among the 86 studies in Ischemic Stroke with a site in Switzerland, this one is the 34th largest by planned enrollment of the 42 interventional ones that give a count, is one of 10 that started in 2025, is one of 4 in phase 2, reaches primary completion later than 23 of the 32 other live ones, and was the 82nd registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

27 of the 86 studies in Ischemic Stroke with a site in Switzerland are open now. Recruiting first, the newest first:

21 more — sign in →

All 27 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 86 studies in Ischemic Stroke with a site in Switzerland, or all of them as a file.
02

Study summary

MASTER is a single-center, patient and investigator-blinded, Randomized Controlled Trial (RCT) to compare the efficacy of Maraviroc, a C-C chemokine receptor 5 (CCR5) antagonist, against placebo regarding motor function and motor learning skills in the first 3 months after ischemic stroke.

Read the detailed description

Stroke is a common disease and one of the leading causes of death and disability worldwide. Despite advances in acute stroke therapies (intravenous thrombolysis and/or mechanical thrombectomy), deficits remain frequent after stroke. Pharmacological approaches have the benefit of being independent of patient participation, are easily administered, and involve limited medical resources. Unfortunately, the efficacy of several drugs that improve behavioural in preclinical models have yet to be confirmed in humans. Maraviroc, a C-C chemokine receptor 5 (CCR5) antagonist has shown promise in preclinical models, and instead of targeting neurotransmitters, is believed to augment rehabilitation by decreasing infarct size, increasing neuroplasticity, and most importantly, improving behaviour.

The MASTER trial is a single-center, double-blinded, randomized placebo-controlled, phase II clinical trial designed to evaluate the efficacy of Maraviroc (Celsentri) compared to a placebo, in improving outcomes following ischemic stroke in the early stage of recovery. 80 patients will be recruited within 5 days of stroke onset, and will receive either Maraviroc or a placebo drug for 90 days.

Participants will be assessed using a combination of clinical measurements, motor tests, and biometrics throughout the 90 days of intervention, and upon follow-up at 6-months post stroke onset. Several types of brain images will be obtained before and after the intervention period (day 0 and day 90), and participants will also perform a motor learning task before and after the intervention period (day 0 and day 90). Study personnel and participants will be blinded to the treatment, which will be randomly assigned to an intervention group with stratification based on side of the infarct and motor deficit.

03

Conditions studied

  • Ischemic Stroke
  • Stroke
  • Stroke Acute

Keywords

  • Ischemic Stroke
  • Maraviroc
  • CCR5
  • Stroke
  • Stroke Acute
  • Motor Recovery
  • Randomized Controlled Trial
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • as documented by signature
  • ≥18 years at time of signing of informed consent
  • Acute ischemic stroke.
  • Stroke onset \< 7 days from randomization.
  • Contralateral, unilateral, incomplete upper limb paresis, incl. :
  • FMA-UE \< 63/66
  • Residual voluntary finger extension (VFE) of > 10 degrees

Exclusion criteria

Exclusion Criteria:

  • Pregnancy/lactation or positive pregnancy test in women of childbearing age
  • Pre-stroke handicap (mRS > 2)
  • Diseases affecting motor function (e.g., Parkinson's Disease, Amyotrophic Lateral Sclerosis (ALS))
  • Participation in another study with medicinal product within 30 days preceding and during the present study
  • Enrolment of the investigator, his/her family members, employees, or other dependent persons
  • Known to Maraviroc, Mannitol, peanuts, or soy
  • History of significant liver disease, hepatitis, elevated liver function tests (> 1.5 )
  • History of significant renal disease or End Stage Renal Disease/dialysis, acute renal injury, (CrCl \< 30ml/min/1.73m2)
  • Patients with cardiovascular comorbidities and risk for orthostatic hypotension
  • infection
  • Concomitant use of strong inhibitors or inducers
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Active comparator
    Maraviroc

    Maraviroc (Celsentri) 300 mg twice daily

    Drug: Maraviroc

  • Placebo comparator
    Placebo

    Placebo (Mannitol) encapsulated

    Drug: Mannitol

Interventions

  • Maraviroc (300mg) twice daily for 90 days

    Also known as: Celsentri

  • DrugMannitol

    Placebo intervention

06

What researchers measure

Primary outcomes

  1. Upper Extremity Fugl-Meyer Assessment (FMA-UE) Score

    Reliable and validated score of motor function of the upper extremities after stroke. Range: 0-66, higher values indicating better motor function.

    Time frame: Day 90

Secondary outcomes

  1. Motor Learning Score

    A motor sequence learning score assessing the capability of the participant to learn a finger tapping sequence of 6 items.

    Time frame: Day 0, 90

  2. Number of adverse events (AE) of special interest

    The number of patients experiencing AE of special interest : MACE (Major Adverse Cardiovascular Events) - Acute myocardial infarction ; Acute coronary syndrome ; Stroke ; Heart failure ; All cause death ; Cardiovascular death ; Revascularization AND any liver adverse events AND any infection adverse events. Assesed by: CTCAE v5.0

    Time frame: Day 0-180 (inclusive)

  3. Number of Serious Adverse Events (SAE)

    Number of any SAEs occuring during the study follow-up. Assessed by: CTCAE v5.0.

    Time frame: 0-180 days (inclusive)

Other outcomes

  1. 9-hole Peg Test (Time)

    The 9-hole peg test is used to measure dexterity. It is measured in seconds to complete the task, with lower duration indicating better dexterity.

    Time frame: Day 0, 30, 60, 90, and 180.

  2. Pinch force

    Pinch force will be measured using a finger dynamometer, measured in kg. A greater value indicates greater finger strength.

    Time frame: Day 0, 30, 60, 90, and 180.

  3. Grip strength

    Grip strength will be measured using a hand dynamometer. Strength is measured in kg, with a greater value indicating stronger grip strength.

    Time frame: Day 0, 30, 60, 90, and 180.

  4. National Institute of Health Stroke Scale (NIHSS)

    A 15-item neurologic examination stroke scale (0 - 42), with higher scores indicating greater neurological impairment.

    Time frame: Day 0, 30, 60, 90, 180

  5. Modified Rankin Scale (mRS)

    An ordinal scale measuring degree of dependence and disability following stroke, ranging from 0 to 6. A lower score indicates greater independence and less disability. 6 indicates death.

    Time frame: Day 0, 30, 60, 90, 180

  6. Barthel Index

    A scale measuring independence for activities of daily living, on a scale from 0 to 100. Higher scores indicate greater functional independence.

    Time frame: Day 0, 30, 60, 90, 180

  7. Functional brain connectivity

    Correlated Blood Oxygen Level Dependent (BOLD) imaging responses in the brain derived from resting state functional MRI scanning (values from 0 to 1, greater values indicating more connectivity), focussing on core motor and peri-infarct functional connectivity.

    Time frame: Day 0, 90

  8. Structural brain connectivity

    Diffusion weighted imaging (DWI) derived structural connectivity, measured as fractional anisotropy of connecting tracts (values of 0 to 1, higher values indicating more directed water diffusion) , focussing on core motor and peri-infarct connectivity.

    Time frame: Day 0, 90

  9. Neurite Density Index

    Microstructure analysis of the brain derived from a multi-shell Diffusion Weighted Imaging (DWI) MRI sequence, using a neurite density index (0 - 1). Greater values indicate greater density of neurites.

    Time frame: Day 0, 90

  10. Brain metabolite concentrations

    Measurement of brain metabolite concentrations - N-acetylaspartate (NAA), Glutamate-Glutamine complex (Glx), Gamma-aminobutyric Acid (GABA), Creatinin (Cr) - using whole-brain magnetic resonance spectroscopic imaging (MRSI).

    Time frame: Day 0, 90

07

Study locations

1 of 1 sites recruiting
  • Geneva University Hospital
    Geneva, Switzerland
    Recruiting
    • Nicolas Broc, MD · Contactnicolas.broc@hug.ch
    • Emmanuel Carrera, MD · Principal investigator
    • Nicolas Broc, MD · Sub investigator
    • Gabriel Byczynski, PhD · Sub investigator
    • Elisabeth Dirren, MD, PhD · Sub investigator
08

References and documents

Publications

  • Joy MT, Ben Assayag E, Shabashov-Stone D, Liraz-Zaltsman S, Mazzitelli J, Arenas M, Abduljawad N, Kliper E, Korczyn AD, Thareja NS, Kesner EL, Zhou M, Huang S, Silva TK, Katz N, Bornstein NM, Silva AJ, Shohami E, Carmichael ST. CCR5 Is a Therapeutic Target for Recovery after Stroke and Traumatic Brain Injury. Cell. 2019 Feb 21;176(5):1143-1157.e13. doi: 10.1016/j.cell.2019.01.044. PubMed 30794775 ↗
  • Sharif A, Jeffers MS, Fergusson DA, Bapuji R, Nicholls SG, Humphrey J, Johnston W, Mitchell E, Speirs MA, Stronghill L, Vuckovic M, Wulf S, Shorr R, Dowlatshahi D, Corbett D, Lalu MM. Preclinical systematic review of CCR5 antagonists as cerebroprotective and stroke recovery enhancing agents. Elife. 2025 Apr 7;14:RP103245. doi: 10.7554/eLife.103245. PubMed 40193175 ↗
  • Broc N, Byczynski G, Dirren E, Carrera E. Maraviroc for Stroke Recovery (MASTER): protocol for a phase 2 double-blind placebo-controlled randomised clinical trial. BMJ Open. 2026 May 3;16(4):e109554. doi: 10.1136/bmjopen-2025-109554. PubMed 42082248 ↗

Individual participant data

Plan to share: Yes — Anonymized patient data of the primary and secondary study outcomes (FMA-UE, global functioning scores, motor learning scores) are currently anticipated to be shared dependent on participant consent to data sharing.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: The IPD and supporting information will be available following the publication of the results (est. 2028) and will be available indefinitely.

Access criteria: IPD will be available in a de-identified format to ensure participant confidentiality. Access will be granted to qualified researchers upon reasonable request, subject to prior approval by the sponsor and the demonstration of approval from a competent ethics committee. The shared data will include de-identified IPD that underlies the results reported in the publication (text, tables, figures, and appendices). Supporting documents such as the study protocol, statistical analysis plan, and clinical study report may also be available. Data will be accessible through a secure platform or via direct request after publication of the main study results.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Dec 2027, 29 months after the start.

Of 82 non-industry phase 2 interventional studies under Ischemic Stroke, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 40. This study's planned 29 months is close to that.

Counting every sponsor, half of 123 studies reached it within 28 months; a quarter within 15 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2025
First posted
Jul 23, 2025
StartActual
Jul 14, 2025
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Aug 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07080567
Lead sponsor
Emmanuel Carrera
Responsible party
Emmanuel Carrera (Sponsor-Investigator, University Hospital, Geneva) — Sponsor-investigator
First posted
Jul 23, 2025
Start date
Jul 14, 2025
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Aug 12, 2025

Study contacts

Emmanuel Carrera, MD
Contact
emmanuel.carrera@hug.ch
+41 (0)22 372 83 18
Nicolas Broc, MD
Contact
nicolas.broc@hug.ch
+41 (0)79 553 38 37
Emmanuel Carrera, MD
principal investigator · Hôpitaux Universitaires Genève

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Maraviroc

Start the discussion